search
Back to results

The Efficacy and Safety of At-home Transcutaneous Electrical Nerve Stimulation in Insomnia

Primary Purpose

Insomnia

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Transcutaneous Trigeminal Electrical Nerve Stimulation using YPS-401B
Sham Stimulation using YPS-401B
Sponsored by
Ybrain Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Insomnia focused on measuring Transcutaneous electric nerve stimulation, TENS, Insomnia, Trigeminal nerve stimulation

Eligibility Criteria

19 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Men and women between the ages of 19 and under 65
  • Those who meet the criteria for the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) for Insomnia
  • Those with a score of 8 or higher based on the Korean version Insomnia severity index (ISI-K)
  • A person whose sleeping environment and habits are regular, usually between 9:00 p.m. and 1:00 a.m., go to bed, lie down for 7 to 10 hours, and wake up between 5 and 10 a.m.
  • In the case of patients who regularly take drugs for improving insomnia at least once a week, those who agree to discontinue taking the prohibited drugs in this study for a total of 5 weeks, 1 week to remove the drug effect after screening and 4 weeks for the clinical study period
  • Persons who do not have a reason to prohibit the use of electrotherapy that can significantly affect biomarkers in relation to this study
  • A person who voluntarily decides to participate and agrees in writing to abide by the precautions after hearing and understanding a sufficient explanation about this clinical trial

Exclusion Criteria:

  • Those who have been diagnosed with sleep arousal disorders other than insomnia (hypersomnia disorder, narcolepsy, breathing-related sleep disorder, circadian rhythm sleep arousal disorder, parasomnia)
  • Those who have insomnia due to physical illness or medications being taken
  • Patients with major medical and neuropsychiatric diseases other than sleep disorders
  • Persons who have had or are currently undergoing dental treatment with a history of implanting metallic materials into the upper body, such as the transcranial or face, neck, etc., where non-invasive electrical stimulation is difficult or impossible
  • Compliance was evaluated by writing a sleep diary for 1 week from the start of treatment, and if a sleep diary of 3 days or less was kept for 1 week, it was excluded from the study.
  • Those who have changed the type and dose of drugs used within the last 3 months, or the type and time of cognitive behavioral therapy
  • If you are currently registered in another clinical trial or use another clinical trial drug or device within 60 days from the time of screening

Exclusion criteria prior to intervention (After the sleep diary for one week after the screening test, if the following criteria are met, the patient will be excluded from participation in the study before the intervention.)

  • Those with less than 8 points based on the Korean version of Insomnia severity index (ISI-K)
  • When writing a sleep diary for a week, if it is written for less than 3 days or has an irregular sleep schedule

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Sham Comparator

    Arm Label

    Experimental group

    Control group

    Arm Description

    Transcutaneous trigeminal nerve stimulation applied using clinical trial medical device (YPS-401B) for 20 minutes every night before going to bed, 28 times for 4 weeks at 1 time / 1 day

    Sham stimulation applied using clinical trial medical device (YPS-401B) for 20 minutes every night before going to bed, 28 times for 4 weeks at 1 time / 1 day

    Outcomes

    Primary Outcome Measures

    Changes in Insomnia Severity Index (ISI)
    Changes in Insomnia Severity Index (ISI) after 4 weeks from pretreatment:

    Secondary Outcome Measures

    Remission rate of ISI
    Remission rate of ISI after 4 weeks compared to before treatment (Remission: ISI score of 7 or less)
    Response rate of ISI
    Response rate of ISI after 4 weeks compared to before treatment (Response: ISI change of more than 7 points or 50% or more decrease)
    Changes in Pittsburgh Slepp Quality Index (PSQI)
    Changes in Pittsburgh Slepp Quality Index (PSQI) after 4 weeks compared to before treatment
    Changes in index of slepp diary
    Changes in index of sleep diary (sleep latency, bedtime, sleep time) after 4 weeks compared to before treatment
    Changes in EEG index
    Changes in EEG index (absolute power, relative power) after 4 weeks compared to before treatment

    Full Information

    First Posted
    September 14, 2022
    Last Updated
    September 19, 2022
    Sponsor
    Ybrain Inc.
    Collaborators
    Seoul National University Bundang Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05546112
    Brief Title
    The Efficacy and Safety of At-home Transcutaneous Electrical Nerve Stimulation in Insomnia
    Official Title
    Pilot Study to Explore the Efficacy and Safety of At-home Transcutaneous Electrical Nerve Stimulation in Insomnia
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    October 4, 2022 (Anticipated)
    Primary Completion Date
    December 31, 2022 (Anticipated)
    Study Completion Date
    December 31, 2022 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Ybrain Inc.
    Collaborators
    Seoul National University Bundang Hospital

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study is to explore the effects and safety of transcutaneous electrical nerve stimulation (TENS) at home for patients diagnosed with insomnia on the improvement of insomnia and nervous stability.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Insomnia
    Keywords
    Transcutaneous electric nerve stimulation, TENS, Insomnia, Trigeminal nerve stimulation

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    30 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Experimental group
    Arm Type
    Experimental
    Arm Description
    Transcutaneous trigeminal nerve stimulation applied using clinical trial medical device (YPS-401B) for 20 minutes every night before going to bed, 28 times for 4 weeks at 1 time / 1 day
    Arm Title
    Control group
    Arm Type
    Sham Comparator
    Arm Description
    Sham stimulation applied using clinical trial medical device (YPS-401B) for 20 minutes every night before going to bed, 28 times for 4 weeks at 1 time / 1 day
    Intervention Type
    Device
    Intervention Name(s)
    Transcutaneous Trigeminal Electrical Nerve Stimulation using YPS-401B
    Intervention Description
    A device that improves insomnia symptoms by transcutaneously applying electrical stimulation including a pulse (10 kHz) burst waveform (10 Hz) to the forehead area to the trigeminal nerve
    Intervention Type
    Device
    Intervention Name(s)
    Sham Stimulation using YPS-401B
    Intervention Description
    A device that is attached in the same way as a real medical device, but actually applies a shum stimulus
    Primary Outcome Measure Information:
    Title
    Changes in Insomnia Severity Index (ISI)
    Description
    Changes in Insomnia Severity Index (ISI) after 4 weeks from pretreatment:
    Time Frame
    after 4 weeks
    Secondary Outcome Measure Information:
    Title
    Remission rate of ISI
    Description
    Remission rate of ISI after 4 weeks compared to before treatment (Remission: ISI score of 7 or less)
    Time Frame
    after 4 weeks
    Title
    Response rate of ISI
    Description
    Response rate of ISI after 4 weeks compared to before treatment (Response: ISI change of more than 7 points or 50% or more decrease)
    Time Frame
    after 4 weeks
    Title
    Changes in Pittsburgh Slepp Quality Index (PSQI)
    Description
    Changes in Pittsburgh Slepp Quality Index (PSQI) after 4 weeks compared to before treatment
    Time Frame
    after 4 weeks
    Title
    Changes in index of slepp diary
    Description
    Changes in index of sleep diary (sleep latency, bedtime, sleep time) after 4 weeks compared to before treatment
    Time Frame
    after 4 weeks
    Title
    Changes in EEG index
    Description
    Changes in EEG index (absolute power, relative power) after 4 weeks compared to before treatment
    Time Frame
    after 4 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    19 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Men and women between the ages of 19 and under 65 Those who meet the criteria for the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) for Insomnia Those with a score of 8 or higher based on the Korean version Insomnia severity index (ISI-K) A person whose sleeping environment and habits are regular, usually between 9:00 p.m. and 1:00 a.m., go to bed, lie down for 7 to 10 hours, and wake up between 5 and 10 a.m. In the case of patients who regularly take drugs for improving insomnia at least once a week, those who agree to discontinue taking the prohibited drugs in this study for a total of 5 weeks, 1 week to remove the drug effect after screening and 4 weeks for the clinical study period Persons who do not have a reason to prohibit the use of electrotherapy that can significantly affect biomarkers in relation to this study A person who voluntarily decides to participate and agrees in writing to abide by the precautions after hearing and understanding a sufficient explanation about this clinical trial Exclusion Criteria: Those who have been diagnosed with sleep arousal disorders other than insomnia (hypersomnia disorder, narcolepsy, breathing-related sleep disorder, circadian rhythm sleep arousal disorder, parasomnia) Those who have insomnia due to physical illness or medications being taken Patients with major medical and neuropsychiatric diseases other than sleep disorders Persons who have had or are currently undergoing dental treatment with a history of implanting metallic materials into the upper body, such as the transcranial or face, neck, etc., where non-invasive electrical stimulation is difficult or impossible Compliance was evaluated by writing a sleep diary for 1 week from the start of treatment, and if a sleep diary of 3 days or less was kept for 1 week, it was excluded from the study. Those who have changed the type and dose of drugs used within the last 3 months, or the type and time of cognitive behavioral therapy If you are currently registered in another clinical trial or use another clinical trial drug or device within 60 days from the time of screening Exclusion criteria prior to intervention (After the sleep diary for one week after the screening test, if the following criteria are met, the patient will be excluded from participation in the study before the intervention.) Those with less than 8 points based on the Korean version of Insomnia severity index (ISI-K) When writing a sleep diary for a week, if it is written for less than 3 days or has an irregular sleep schedule
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Kiwon Lee, PhD
    Phone
    +82-535-2871
    Email
    clinical.trials@ybrain.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Jinuk Kim, PhD
    Phone
    +82-10-5185-4561
    Email
    jinuk.kim@ybrain.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Changho Yoon, MD, PhD
    Organizational Affiliation
    Seoul National University Bundang Hospital
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided

    Learn more about this trial

    The Efficacy and Safety of At-home Transcutaneous Electrical Nerve Stimulation in Insomnia

    We'll reach out to this number within 24 hrs